Additional file 2 of Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies

Additional file 2: Table S1. Enrichment of gold standard genes by feature and GWAS study source. Table S2. Precision and recall of different features to recover gold standard genes. Table S3. Genes with predicted gain or loss of function variants (P<1x10-6). Table S4. Genes with overrepresented disease categories of GWAS in which they are prioritized as causal. Table S5. Genes with overrepresented cell-type colocalizing QTL with GWAS in which they are prioritized as causal. Table S6. Significantly enriched colocalizing QTL cell types and tissues in disease GWAS categories, after grouping similar tissues and cell-types together. Table S7. Significantly enriched colocalizing QTL cell types and tissues in disease GWAS categories, treating each eQTL dataset separately. Table S8. Enrichment of prioritized genes by feature across clinical trial phases and approved drugs. Table S9. Enrichment of prioritized genes by rank across clinical trial phases and approved drugs. Table S10. Putative causal association between diseases and IL6, IL6ST, or IL6R.